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In mammals, the Raf family of
serine/threonine kinases comprises
three members: Raf-1, A-Raf, and B-Raf.
The best-studied representative, Raf-1,
features a complex regulation that
involves binding to activated Ras,
dephosphorylation of inhibitory sites and
phosphorylation of activating sites, and
interactions with scaffolds, effectors, and
lipid and protein regulators (Kolch,
2000). B-Raf regulation appears to be
much simpler, with Ras binding and acti-
vation loop phosphorylation on T598 and
S601 sufficing for full activation. Once
activated, all Raf kinases can phospho-
rylate MEK, which in turn phosphory-
lates and activates ERK. Recently, B-Raf
has taken center stage due to the discov-
ery that it is mutated in prevailing human
cancers, including 60% of malignant
melanomas and 5%–15% of colon, ovar-
ian, and thyroid carcinomas (Davies et
al., 2002). The most common mutation is
V599E, which dramatically enhances B-
Raf activity, presumably because its neg-
ative charge mimics activation loop
phosphorylation. However, substitution
of V599 by positively charged residues
was also found in tumors. Even more
puzzling, a small (?10%) number of
tumors contain mutations in the ATP
binding site (P loop) and the conserved
DFG motif at the beginning of the activa-
tion loop, which only modestly activate or
even impair B-Raf activity.These findings
pose the questions of how B-Raf is acti-
vated and how these mutations con-
tribute to tumorigenesis.
A recent study sheds new light on
these important questions. Wan et al.
(2004) solved the structure of the isolat-
ed B-Raf and B-RafV599E kinase
domain. As B-Raf was dephosphorylated
and crystallized in the presence of the
Raf inhibitor BAY43-9006, the structure
probably captures the inactive conforma-
tion of B-Raf. It exhibits the characteristic
bilobal structure of protein kinases, most
closely resembling that of c-Abl and p38.
B-Raf residues G595-V599 of the activa-
tion loop engage in hydrophobic interac-
tions with residues G463-V470 of the P
loop. In this conformation, the catalytic
residues are not aligned for ATP and
substrate binding. Oncogenic B-Raf
mutations either in the P loop or activa-
tion loop destabilize their interaction and
disrupt the inactive conformation (Figure
1A). However, only few mutations enable
the formation of critical new interactions
that fold the kinase into a catalytically
competent structure. Thus, the crystal
structure beautifully explains why the P
loop and the activation loop are preferred
mutational targets. However, it leaves as
a riddle why some tumors select for
mutations that impair catalytic activity.
Wan et al. (2004) classify B-Raf
mutants into three groups possessing
high, intermediate, or low in vitro kinase
activity. The high-activity group exceeds
wild-type B-Raf activity 100- to 700-fold,
with the V599E mutation being 460-fold
activated. The intermediate group con-
tains B-Raf mutants with 1- to 10-fold
activity, whereas the low-activity group is
less active than B-Raf. Surprisingly, this
large variation in mutant B-Raf kinase
activities did not translate into differential
ERK activity. The high and intermediate
B-Raf mutants only raised ERK activity
2- to 4.6-fold. How is this wide range of
B-Raf activities buffered into a narrow
bandwith of ERK activities? Obviously,
there must be regulatory gates that con-
trol the signal flow from Raf to MEK and
ERK. Candidates are scaffolding pro-
teins such as KSR and protein interac-
tion disruptors such as RKIP (Kolch,
2000). A future challenge will be to iden-
tify these gatekeepers and their physio-
logical function. Why is ERK activity so
strictly controlled? Hyperactivation of the
ERK pathway can induce cell cycle
arrest (Ravi et al., 1998) and senes-
cence (Zhu et al., 1998), events which a
tumor obviously must avoid. A more sub-
tle facet is that the kinetics and amplitude
of ERK signaling can specify different
biological programs, such as prolifera-
tion or differentiation of PC12 cells
(Marshall, 1995). Conceivably, a tumor
would select for ERK activities that pro-
gram the cell for growth and survival.
Remarkably, three out of four low-
activity B-Raf mutants also induced ERK
activation. Wan et al. show that this is
due to the activation of Raf-1 by the
respective B-Raf mutants (Wan et al.,
2004). High- and intermediate-activity B-
Raf mutants also activated Raf-1 but in
contrast to low-activity mutants did not
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Figure 1. B-Raf activation by mutation
A: B-Raf mutations cluster in the P loop and
activation loop. These loops interact via a
hydrophobic interface (shaded blue) includ-
ing an important contact between F467 and
V599. Activating phosphorylation on T598
and S601 is indicated. Mutations analyzed by
Wan et al. are color coded (red, low activity;
orange, medium activity; green, high
activity). 
B: Low-activity B-Raf mutants stimulate ERK
through Raf-1.
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rely on Raf-1 for ERK stimulation (Figure
1B). The mechanism of transactivation
remains unsolved. It is not due to
autocrine stimulation but rather seems
related to the fact that Raf-1 forms het-
erodimers with B-Raf and equally effi-
ciently with B-Raf mutants. However,
while most B-Raf mutants activated Raf-
1, wild-type B-Raf and two B-Raf
mutants devoid of kinase activity failed.
The latter include the tumor-derived
D593V mutant in the DFG motif and an
engineered mutation, K482M, which is
commonly used to generate kinase-neg-
ative mutants by changing the critical
catalytic lysine. These observations sug-
gest that B-Raf must be both in an acti-
vated conformation and retain at least
some kinase activity to activate Raf-1.
Interestingly, B-Raf has been identified
biochemically as component of a 400
kDa Ras-induced Raf-1 activator com-
plex (Mizutani et al., 2001). Hence, trans-
activation of Raf-1 may involve activating
transphosphorylation, recruitment of
other Raf-1 activators, or inactivation of
Raf-1 inhibitors by B-Raf. It will be inter-
esting to elucidate what the physiological
role of the Raf-1/B-Raf complex is and
how exactly B-Raf mutations subvert its
regulation.
Another intriguing finding of the Wan
et al. study (Wan et al., 2004) is that the
low-activity B-Raf mutants did not trans-
form NIH 3T3 fibroblasts although they
could stimulate ERK.This could represent
a simple threshold phenomenon, as
transformation may require a certain level
of ERK activity. However, it also could
reflect a more subtle function of this class
of B-Raf mutants, as hinted to by the phe-
notype of a Raf-1 mutant where the
inhibitory S259 was changed. This Raf-1
mutant activates ERK to levels that are
indistinguishable from oncogenic v-Raf
and stimulates the proliferation of NIH
3T3 cells yet fails to transform (Dhillon et
al., 2003). Thus, similar ERK activities
may produce distinct biological responses
depending on the upstream mode of acti-
vation. This reemphasizes the question of
what role the different B-Raf mutants play
in tumorigenesis. Ras and strongly acti-
vating B-Raf mutations generally are not
found in the same tumor, arguing that B-
Raf can fully substitute for Ras and is its
main effector in oncogenesis (Davies et
al., 2002). However, where Ras and B-Raf
mutations coincide, such as in some
colon carcinomas, B-Raf mutants fall in
the intermediate- and low-activity groups
(Yuen et al., 2002), suggesting that Ras
and B-Raf mutations are coselected
because they supply complementary
functions to the tumor. It will be instructive
to reveal what these functions are.
A related question is why there are
so many different B-Raf mutations. The
frequency of B-Raf mutations but not of
K-Ras mutations is elevated in mismatch
repair-deficient colon tumors, suggesting
that B-Raf mutations are favored by
intrinsic faults in DNA repair, while Ras is
mainly targeted by environmental car-
cinogens. B-Raf mutations are typically
somatically acquired and occur early,
often in premalignant lesions. Most strik-
ingly, ?80% of nevi harbour B-RafV599E
mutations without featuring ERK hyper-
activation and progression to malignan-
cy. On the other hand, mutated B-Raf
seems to be required at later stages of
melanoma progression (Mercer and
Pritchard, 2003). This apparent paradox
could point to a dual function of B-Raf or
the existence of B-Raf inhibitors that are
lost during progression.Wan et al. (2004)
have set the stage to unravel the molecu-
lar function of B-Raf in tumorigenesis.
The major challenge ahead is now to
define its pathophysiological role.
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